Global Gout Therapeutics Market - Segmented by Drug Class, Application, and Geography - Growth, Trends, and Forecast (2022 - 2030)
Gout Therapeutics Market Overview
The Gout Therapeutics Market is expected to grow, at a CAGR of approximately 15% during the forecast period. The recent years has observed growing acceptance of the drugs owing to their capability to yield powerful anti-inflammatory action, with several others currently undergoing clinical trials which are anticipated to be marketed during the forecast period and are expected to drive the market. Some of the marketed products include Krystexxa, Colcrys, Zyloprim, among others which is the approved by the US FDA for gout. On the basis of regional analysis, North America is among the most lucrative region owing to increased awareness in society, multiple major player’s wide presence with their branded products, increasing use of imaging modalities to diagnose gout in better healthcare facilities.
Increasing Alcohol Consumption and the Associated Risk of Gout to Induce a Surge in the Gout Therapeutics Market
There are several studies conducted in past to relate the lifestyle factors contributing to Gout prevalence. Among them, as per a 2015 publication in the “American Journal of Medicine”, it was reported that there was a significant dose-response relationship between the amount of alcohol consumption and risk of recurrent gout attacks. Similar results were replicated by other studies. As per the National Survey on Drug Use and Health (NSDUH) conducted in 2015, it was found that 86.4 % of people aged 18 or older reported drinking alcohol at some point in their lifetime. 70.1 % reported that they drank in the past year; 56.0 % reported that they drank in the past month. Based on the above-mentioned statistics and considering the association between alcoholism and gout it can be expected that increasing alcohol consumption among the primary factor driving the gout therapeutics market over the forecast period.
Other contributing drivers include rising adoption of biologics, with increased R&D on regenerative medicines and technological advancements in imaging modalities improving the gout understanding and clinical applications.
Side Effects of Gout Therapeutic Drugs to Impede the growth of Gout Therapeutics Market
Colchicine is the most common drug deployed for the treatment of gout. Colchicine-induced myopathy and neuropathy might be more recurrent than formerly recognized, and hence patients undergoing long-term therapy must be supervised continuously. Bone marrow depression has been informed, mainly in cases of severe colchicine intoxication, and intravenous administration of the drug has been associated with acute pancytopenia and in some cases even death. Because of its cytogenic effects and reported association with Down's syndrome, the agent should not be used by pregnant women. In addition, the adverse effects affects the complete treatment procedure which raising multiple other disorders such in 2018, high rates of cardiovascular events were reported from the drug febuxostat. Along with slow awareness, these limitations of gout therapeutics results are expected to hamper the growth of the gout therapeutics market.
Another limitation considered under the scope of the study include high indirect cost associated with gout therapeutics.
Asia-Pacific to Emerge as the Fastest Growing Region for the Gout Therapeutics Market
The Asia Pacific countries are anticipated to witness the fastest growth over the forcasted period for this market with the presence of several high econmically growing countries such as India, China, South Korea, and other South Asian countries. The factors such as diversified patient pool, increasing investment by major players with local manufacturers and hospital chains such as Brii Biosciences launched “bring innovative medicines to chinese patients” in collaboration with several pharma firms globally including Ardea Biosciences (AstraZeneca) for gout, raises the growth opportunities and adoption rate in the emerging markets. Additionally, lifestyle factors such as increasing smoking prevalence & alcohol consumption and stressed lifestyle is likely to boost the incidence of gout over the period, 2018-2023.
Key Developments in the Market
• May, 2018: National Gout Awareness Day and the American Kidney Fund (AKF) collaborated and secured grant to develop gout education campaign and its connection with kidney disease.
• Aug, 2017: Ironwood Pharmaceuticals received US Food and Drug Administration (US FDA) approval of DUZALLO (lesinurad and allopurinol), for the patient treatment suffering from Hyperuricemia, an uncontrolled gout.
Major Players: ASTRAZENECA PLC, BOEHRINGER INGELHEIM, GLAXOSMITHKLINE PLC, HORIZON PHARMA PLC, MERCK & CO. INC, NOVARTIS, REGENERON PHARMACEUTICALS, SAVIENT PHARMACEUTICALS, TAKEDA PHARMACEUTICAL COMPANY LTD., and TEIJIN PHARMA LTD, among others.
Reasons to Purchase the Gout Therapeutics Market Report
• Current and future Gout Therapeutics Market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the market estimate sheet (in Excel)
Customization of the Gout Therapeutics Market Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
The Gout Therapeutics Market is expected to grow, at a CAGR of approximately 15% during the forecast period. The recent years has observed growing acceptance of the drugs owing to their capability to yield powerful anti-inflammatory action, with several others currently undergoing clinical trials which are anticipated to be marketed during the forecast period and are expected to drive the market. Some of the marketed products include Krystexxa, Colcrys, Zyloprim, among others which is the approved by the US FDA for gout. On the basis of regional analysis, North America is among the most lucrative region owing to increased awareness in society, multiple major player’s wide presence with their branded products, increasing use of imaging modalities to diagnose gout in better healthcare facilities.
Increasing Alcohol Consumption and the Associated Risk of Gout to Induce a Surge in the Gout Therapeutics Market
There are several studies conducted in past to relate the lifestyle factors contributing to Gout prevalence. Among them, as per a 2015 publication in the “American Journal of Medicine”, it was reported that there was a significant dose-response relationship between the amount of alcohol consumption and risk of recurrent gout attacks. Similar results were replicated by other studies. As per the National Survey on Drug Use and Health (NSDUH) conducted in 2015, it was found that 86.4 % of people aged 18 or older reported drinking alcohol at some point in their lifetime. 70.1 % reported that they drank in the past year; 56.0 % reported that they drank in the past month. Based on the above-mentioned statistics and considering the association between alcoholism and gout it can be expected that increasing alcohol consumption among the primary factor driving the gout therapeutics market over the forecast period.
Other contributing drivers include rising adoption of biologics, with increased R&D on regenerative medicines and technological advancements in imaging modalities improving the gout understanding and clinical applications.
Side Effects of Gout Therapeutic Drugs to Impede the growth of Gout Therapeutics Market
Colchicine is the most common drug deployed for the treatment of gout. Colchicine-induced myopathy and neuropathy might be more recurrent than formerly recognized, and hence patients undergoing long-term therapy must be supervised continuously. Bone marrow depression has been informed, mainly in cases of severe colchicine intoxication, and intravenous administration of the drug has been associated with acute pancytopenia and in some cases even death. Because of its cytogenic effects and reported association with Down's syndrome, the agent should not be used by pregnant women. In addition, the adverse effects affects the complete treatment procedure which raising multiple other disorders such in 2018, high rates of cardiovascular events were reported from the drug febuxostat. Along with slow awareness, these limitations of gout therapeutics results are expected to hamper the growth of the gout therapeutics market.
Another limitation considered under the scope of the study include high indirect cost associated with gout therapeutics.
Asia-Pacific to Emerge as the Fastest Growing Region for the Gout Therapeutics Market
The Asia Pacific countries are anticipated to witness the fastest growth over the forcasted period for this market with the presence of several high econmically growing countries such as India, China, South Korea, and other South Asian countries. The factors such as diversified patient pool, increasing investment by major players with local manufacturers and hospital chains such as Brii Biosciences launched “bring innovative medicines to chinese patients” in collaboration with several pharma firms globally including Ardea Biosciences (AstraZeneca) for gout, raises the growth opportunities and adoption rate in the emerging markets. Additionally, lifestyle factors such as increasing smoking prevalence & alcohol consumption and stressed lifestyle is likely to boost the incidence of gout over the period, 2018-2023.
Key Developments in the Market
• May, 2018: National Gout Awareness Day and the American Kidney Fund (AKF) collaborated and secured grant to develop gout education campaign and its connection with kidney disease.
• Aug, 2017: Ironwood Pharmaceuticals received US Food and Drug Administration (US FDA) approval of DUZALLO (lesinurad and allopurinol), for the patient treatment suffering from Hyperuricemia, an uncontrolled gout.
Major Players: ASTRAZENECA PLC, BOEHRINGER INGELHEIM, GLAXOSMITHKLINE PLC, HORIZON PHARMA PLC, MERCK & CO. INC, NOVARTIS, REGENERON PHARMACEUTICALS, SAVIENT PHARMACEUTICALS, TAKEDA PHARMACEUTICAL COMPANY LTD., and TEIJIN PHARMA LTD, among others.
Reasons to Purchase the Gout Therapeutics Market Report
• Current and future Gout Therapeutics Market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the market estimate sheet (in Excel)
Customization of the Gout Therapeutics Market Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
